Novavax Delays U.S. Trial Start Of COVID-9 Vaccine To November
The company said it would begin the trial by the end of November. It previously expected to start this month.
The company said it had expanded its enrollment target in the UK trial to 15,000 volunteers from 10,000. It expects this could help assess safety and effectiveness of the vaccine in a shorter time period.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor